The growing inclination for biologics and biosimilars is driving the sterile injectable contract manufacturing market.New ...

The European Commission is expected to give unconditional approval for the $16.5 billion purchase of Catalent (NYSE: CTLT) as ...

Novo Holdings is set to gain unconditional EU antitrust approval for its planned $16.5 billion takeover of U.S. contract drug ...

EU antitrust regulators are set to clear without conditions Novo Holdings' planned $16.5 billion takeover of Catalent, a ...

On Wednesday, Catalent Inc (CTLT) stock saw a modest uptick, ending the day at $61 which represents a slight increase of $0.25 or 0.41% from the prior close of $60.75. The stock opened at $60.95 and ...

Charles Schwab Investment Management Inc. boosted its stake in Catalent, Inc. (NYSE:CTLT – Free Report) by 1.1% during the ...

Will the Novo-Catalent merger be challenged under the new Trump administration? A former FTC policy director thinks so.

Update 12:35pm: Adds Reuters report. Catalent (NYSE:CTLT) rose 2.2% amid reports that the European Union's antitrust regulator will likely grant approval for its planned sale to Novo Holdings ...

StockNews.com downgraded shares of Catalent (NYSE:CTLT – Free Report) from a hold rating to a sell rating in a report released on Friday morning. CTLT has been the topic of several other ...

Novo Holdings, the controlling shareholder of Novo Nordisk (NVO), is slated to received unconditional EU antitrust approval for its proposed ...

With a market cap of $10.7 billion, Catalent, Inc. (CTLT) is a leading global provider of advanced delivery technologies and development solutions for drugs, biologics, and consumer health products.

Contract manufacturing revenues in the pharmaceutical finished dose sector witnessed a significant slowdown over the past ...